Rare Disease Report

Protalix's Plant Derived Fabry ERT in Phase 3 Study

FEBRUARY 22, 2017
Einat Brill-Almon, PhD



Einat Brill-Almon, PhD, senior vice president of product development at Protalix Biotherapeutics talks about the company's enzyme replacement therapy (pegunigalsidase alfa) for patients with Fabry disease. The company is currently enrolling patients in a phase 3 clinical trial.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.